Clearside Biomedical (CLSD) Set to Announce Earnings on Tuesday

Clearside Biomedical (NASDAQ:CLSD) will be announcing its earnings results after the market closes on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link.

Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.04. The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.25 million. During the same period in the previous year, the business posted ($0.15) earnings per share. On average, analysts expect Clearside Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Clearside Biomedical Price Performance

CLSD opened at $1.14 on Friday. The stock has a market capitalization of $85.19 million, a price-to-earnings ratio of -2.28 and a beta of 2.33. Clearside Biomedical has a 12 month low of $0.76 and a 12 month high of $2.12. The business has a 50-day moving average of $1.18 and a two-hundred day moving average of $1.19.

Wall Street Analyst Weigh In

Several brokerages recently commented on CLSD. Needham & Company LLC upped their price target on shares of Clearside Biomedical from $4.00 to $6.00 and gave the stock a “buy” rating in a research report on Thursday, October 10th. Chardan Capital restated a “buy” rating and set a $6.00 price objective on shares of Clearside Biomedical in a report on Monday, October 14th. HC Wainwright reiterated a “buy” rating and issued a $5.00 target price on shares of Clearside Biomedical in a report on Tuesday, August 27th. Finally, StockNews.com lowered Clearside Biomedical from a “hold” rating to a “sell” rating in a research note on Friday. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $5.17.

Insider Buying and Selling

In related news, insider Ngai Hang Victor Chong bought 36,500 shares of the stock in a transaction dated Friday, November 1st. The stock was acquired at an average price of $1.00 per share, for a total transaction of $36,500.00. Following the completion of the purchase, the insider now owns 100,000 shares in the company, valued at $100,000. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.20% of the stock is owned by corporate insiders.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD.